Copyright ONCO-THAI

Synaps gathers scientific and clinical teams in Europe, to enhance the treatment of glioblastomas using laser-based photodynamic therapies.

Photodynamic therapy (PDT) consists in exposing photosensitized tumour tissues to laser light, triggering the formation of molecules that kill malignant cells. This technology is potentially able to reach and selectively destroy tumour cells that cannot be removed through surgical resection. Beyond its efficacy, PDT is harmless for patient and thus deserves to be added in standard of care protocols.

Synaps: a research network to develop a new therapeutic approach

Despite demonstrating promising efficacy, PDT cannot be used today as a standard therapeutic modality because of the lack of reliable and reproducible therapy schemes, consensus on a photosentisizer and controlled multicentre clinical trial results.
Synaps brings together specialized research and clinical teams across Europe, to tackle these challenges and develop a promising therapy.